Insmed Inc. (INSM): Ph2b TPIP PAH数据超预期

10 June 2025 | 4:36PM EDT Insmed Inc. (INSM): Positive Ph2b TPIP PAH data surpass expectations INSM reported positive topline data from the Ph2b TPIP PAH trial with the study meeting all primary and secondary efficacy endpoints. Notably, TPIP treatment (measured 24 hours at trough, and thereby supportive of once daily dosing) resulted in 35% placebo-adjusted reduction from baseline in PVR (p<0.001) and 35.5m placebo-adjusted improvement in 6MWT (p=0.003), consistent with our bull case scenario and driving s ...